Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: N4 Pharma hails "encouraging" siRNA research

Thu, 07th Dec 2023 18:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Etablissements Maurel & Prom SA, a Paris-based, energy industry-focused company, says it is moving closer to acquiring Wentworth. Explains that it has signed an agreement with the Tanzania Petroleum Development Corporation, which is structured as a 'call option' and allows Tanzania Petroleum to increase its ownership in the production interest by up to 20%. Wentworth has arranged for the Jersey Court to consider and possibly sanction the scheme at a hearing on December 19. Following this date, M&P will take ownership of Wentworth and acquire its 32% direct and indirect interest in Mnazi Bay. Subsequent to the closing of the Acquisition, M&P expects Tanzania Petroleum this call option, meaning that M&P will hold a 60% ownership in Mnazi Bay, and Tanzania Petroleum will hold 40%. M&P says the joint operating agreement will be changed to reflect these new partnership conditions. Adds that it will fund the acquisition with the GBP63 millio placed in escrow.

----------

N4 Pharma PLC - Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines - Says that its work-to-date on its ongoing in vitro small interfering ribonucleic acid research, or siRNA, is "very encouraging", and shows that Nuvec has "considerable potential" to be able to knockdown two independent pathways leading to "more effective "cancer treatments. Explains that it has been investigating the ability of Nuvec nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. After confirming dual loading of Nuvec, N4 then tested the effect of BRD4 combined with EGFR and PLK1 combined with EGFR on knockdown and cell viability. Says that when when loaded together there was an interaction which resulted in a reduction in knockdown of EGFR receptor, though the reduction on cell viability was retained. It is now exploring varying the amount of each siRNA loaded on Nuvec, and also looking at how low the dose can be reduced to still achieve a functional cell inhibition endpoint. In terms of strategy moving forwards, says that that the precise combinations of siRNA, both in terms of target and concentration of siRNA, will vary depending in which cell type they are tested in.

----------

Software Circle PLC - Manchester-based printing and software company - Regarding the sale of Works Manchester Ltd, says that Works Manchester has filed a notice of intention to appoint administrators. This follows an earlier announcement in June, when Software said it had not received the first instalment of deferred consideration from Rymack Sign Solutions Ltd to buy Works Manchester. Further, due to reduced confidence of receiving payment of any deferred consideration from Rymack, the carrying value of the GBP2.81 million due under the sale and purchase agreement has been reduced to GBP350,000. Software is in the process of taking steps to recover the sums due, and says it will update the market again in due course. Adds that the Nettl Systems management team have been making arrangements with alternative suppliers so that continuity of supply is in place for products available through the Nettl Systems platform.

----------

Ecofin US Renewables Infrastructure Trust PLC - Investor in US renewable energy assets - Expects its Whirlwind Energy wind asset in in Floydada, Texas to reenergise in mid-December, after moving "significantly closer" to coming back online. Says that AEP, the owner of the Matador and Paducah substations, has now finished testing a new transmission line past Matador to Paducah. Adds that the first payment on its business interruption coverage has now been received and further payments are scheduled to follow, "substantially mitigating lost revenue". Meanwhile, the Ellis Road solar farm in Westminster, Massachusetts is back online, following a rodent infestation. Finally, says that progress continues to be made on a previously announced strategic review. Says there can be no certainty as to the outcome of the review or any asset sale process, nor whether any potential transaction or transactions arising could be successfully completed.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Jun 2018 11:54

N4 Pharma Says Team Making Progress In Nuvec Manufacturing Process

LONDON (Alliance News) - Drug reformulator N4 Pharma PLC said Monday work to develop a manufacturing process for Nuvec has begun "well" with the team making progress.Nuvec is a to

Read more
9 May 2018 14:13

N4 Pharma Files Patent For Drug To Treat Premature Ejaculation

LONDON (Alliance News) - Pharmaceutical company N4 Pharma PLC announced on Wednesday it has filed a patent application for a treatment for premature ejaculation.N4 Pharm's drug is an of

Read more
25 Apr 2018 11:54

N4 Pharma Outlook Optimistic But Loss Widens After Reverse Takeover

LONDON (Alliance News) - N4 Pharma PLC on Wednesday said it remains optimistic for future as progresses its drug and vaccine development, but the company's loss widened in 2017 following its a

Read more
18 Apr 2018 12:15

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

LONDON (Alliance News) - N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the of a

Read more
9 Mar 2018 10:43

N4 Pharma Raises Nets GBP159,700 From Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Friday it issued 1.9 million shares due to exercise of warrants, raising GBP159,700 for the pharmaceutical warrants

Read more
8 Mar 2018 13:34

N4 Pharma Unveils Two-Pronged Strategy For Nuvec Development

LONDON (Alliance News) - N4 Pharma PLC announced Thursday a two-fold development strategy for its Nuvec technology, as well as a new head of development for Nuvec.Nuvec

Read more
7 Mar 2018 12:41

N4 Pharma Raises Further GBP30,451 After Warrant Exercise (ALLISS)

LONDON (Alliance News) - N4 Pharma PLC said Wednesday it issued 358,245 shares due to exercise of warrants, raising GBP30,451 for the pharmaceutical warrants at

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.